Sylvia Mcbrinn

Sylvia Mcbrinn

Director/Board Member at BIOATLA, INC.

Net worth: 52 030 $ as of 2024-03-30

71 year
Health Technology
Consumer Services
Technology Services

Profile

Propel Bio Partners Senior Advisor Sylvia McBrinn is also a strategic Board Director, CEO, and commercialization expert with 30+ years of leadership experience in the biopharmaceutical industry.
With a strong commercial background in US and global markets, she has led successful launches of specialty to blockbuster products and grown market share for companies including Pfizer and Vernalis.
She provides biopharmaceutical companies critical insights from a career of executive governance, operational, and commercial success across a wide range of therapeutic areas including neurology, inflammation and rheumatology, pain, infectious disease/microbiome, and urology.
Currently, she serves and advises BioAtla (Nasdaq: BCAB) as Board Director, Compensation Committee Chair, and Audit Committee member, and as a Board Director of Ilya Pharma (private).
Until recently, she led as Board Director/founding CEO of early-stage biotech company Axerion Therapeutics (now ReNetX Bio), and also built and led the US subsidiary of a British biotech, Vernalis, with full P&L oversight.
Earlier, she was an EVP and GM of Andrx with full P&L responsibility, overseeing branded products with 400 employees across key business functions.
Throughout her career and board roles, she has earned a reputation of a strategic thinker with the ability to connect the dots and ask insightful questions between business direction, portfolio strategy, R&D, marketing, and commercialization.
As Global VP of Marketing at Pfizer, Ms. McBrinn led the launch and commercialization of the blockbuster product Bextra—the #1 Product launch in the US that year—achieving $1B in sales in the first 12 months and exceeding forecast by 35%.
Additionally, she built the #1 Parkinson’s disease product franchise globally, exceeding forecast by 40%.
At Vernalis, she in-licensed and relaunched Apokyn, an injectable Parkinson’s product that increased sales 42% YOY.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2023-12-25 15,125 ( 0.03% ) 52 030 $ 2024-03-30

Sylvia Mcbrinn active positions

CompaniesPositionStart
BIOATLA, INC. Director/Board Member 2021-06-14
Corporate Officer/Principal -
Consultant / Advisor 2022-02-28
All active positions of Sylvia Mcbrinn

Former positions of Sylvia Mcbrinn

CompaniesPositionEnd
Director/Board Member 2023-05-31
Founder 2011-12-31
Vernalis Pharmaceuticals, Inc. Corporate Officer/Principal 2008-11-30
Corporate Officer/Principal 2003-12-31
Pharmacia & Upjohn, Inc. Corporate Officer/Principal -
See the detail of Sylvia Mcbrinn's experience

Training of Sylvia Mcbrinn

DeSales University Undergraduate Degree
Widener University Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Sylvia Mcbrinn's experience

Connections

50

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
BIOATLA, INC.

Health Technology

Private companies9
Pharmacia & Upjohn, Inc.

Health Technology

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Vernalis Pharmaceuticals, Inc.

Health Technology

Finance

See company connections
  1. Stock Market
  2. Insiders
  3. Sylvia Mcbrinn